STRO
SUTRO BIOPHARMA, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 23 ▼ Sutro Biopharma has filed an S-3 shelf registration allowing it to r…
- Mar 23 ▲ Sutro Biopharma reported its 2025 financial results, highlighted by…
- Apr 19 FDA: Sutro Biopharma Presents Promising Preclinical Data Across…
- Apr 19 ▲ Sutro Biopharma presented promising preclinical data for its next-ge…
- May 28 Barclays initiates
- Aug 12 ▲ Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) an…
- Aug 12 Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY fr…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 16 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
18 of 20 rate it Buy or better.
- Short sellersBUILDING
Short interest +15.1% to 2.26M shares. 6.3 days to cover, ≈13.6% of shares.
- TrendDOWNTREND
28% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | DOUBLED | $6.1M |
| MARSHALL WACE, LLP | ADD | $5.1M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $4.6M |
| JPMORGAN CHASE & CO | ADD | $3.6M |
| FMR LLC | DOUBLED | $2.8M |
| UBS Group AG | TRIM | $1.9M |
| MACKENZIE FINANCIAL CORP | TRIM | $1.1M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $1.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Barclays MAINTAIN | Overweight |
| Oct 15, 2026 | Wedbush REITERATE | Outperform |
| Aug 13, 2026 | Citizens MAINTAIN | Market Outperform |
| Aug 13, 2026 | Wedbush REITERATE | Outperform |
| May 28, 2026 | Barclays INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER Sep 18, 2026 | TAX W/H | $20.6K |
Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER Sep 18, 2026 | EXERCISE | 3,750 sh |
MATSUI CONNIE Director Jun 5, 2026 | AWARD | 10,000 sh |
Dybbs Michael Director Jun 5, 2026 | AWARD | 10,000 sh |
Hunter Heidi Director Jun 5, 2026 | AWARD | 10,000 sh |
Jagpal Sukhi Director Jun 5, 2026 | AWARD | 10,000 sh |
Lobacki Joseph M Director Jun 5, 2026 | AWARD | 10,000 sh |
PANEK JAMES P Director Jun 5, 2026 | AWARD | 10,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
6 filings · 2 press releases · 1 bullish · 2 bearish · 1 mixed · 2 neutral- BEARISH PRESS-RELEASENov 12, 2026
Sutro Biopharma reported Q3 2026 revenue of $9.1M (below the $14.1M consensus) and GAAP EPS of…
Revenue missed consensus by a wide margin, driven by lower collaboration revenue. The EPS beat is not meaningful given the different share count and expense base. Monitor upcoming clinical data for…
- NEUTRAL SC 13GNov 9, 2026
Coastlands Capital LP disclosed a new 5.14% passive stake in Sutro Biopharma, holding 852,669…
Monitor for any subsequent amendments or a potential conversion to a 13D if the fund's intent changes. The stake is just above the 5% threshold, so further accumulation or reduction will trigger…
- BULLISH 8-KAug 12, 2026
Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS…
The STRO-004 early clinical data is the primary catalyst, validating the platform and de-risking the pipeline. Traders should monitor for the next STRO-004 update in 1H 2027 and the initiation of…
- MIXED PRESS-RELEASEAug 12, 2026
Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY from $63.7M) and a net loss of…
The weak financials (revenue collapse, widening loss) are secondary to the STRO-004 clinical data, which provides the first proof-of-concept for Sutro's platform. The stock will likely trade on the…
All STRO filing & press-release reports (8)
- PRESS-RELEASE reportNov 12, 2026
- SC 13G reportNov 9, 2026
- 8-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- DEFA14A reportApr 22, 2026
- PRESS-RELEASE reportApr 19, 2026
- S-3 reportMar 23, 2026
- PRESS-RELEASE reportMar 23, 2026